Samsung Securities Valuation Multiples

Discover Samsung Securities' revenue and EBITDA valuation multiples and investment history, alongside public comparables like Zheshang Securities, Brookfield Business Corp, HuaAn Securities, Dongxing Securities and more.

Samsung Securities Overview

About Samsung Securities

Samsung Securities Co Ltd provides customised asset management services to individual investors, as well as brokerage services to institutional investors. The company operates through three major segments: wealth management, which offers tailored wealth management and retirement planning services; sales and trading, which provides financial products such as equities, equity-linked products, fixed-income, currencies, and commodities; and the investment banking segment, which offers corporate financing services that include stock offerings or initial public offerings, issuance of multiple types of bonds, and investment banking services. The company’s revenue stems from brokerage commissions, fund sales, and underwriting and advisory commissions.


Founded

1982

HQ

South Korea

Employees

N/A

Financials (LTM)

Revenue: $2.1B
Net Income: $934M

EV

$14B

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Samsung Securities Financials

Samsung Securities reported last 12-month revenue of $2.1B.

In the same LTM period, Samsung Securities generated $934M in net income.

Revenue (LTM)


Samsung Securities P&L

In the most recent fiscal year, Samsung Securities reported revenue of $1.7B and net income of $690M.

Samsung Securities is profitable as of last fiscal year, with net margin of 40%.

See analyst estimates for Samsung Securities
LTMLast FY202320242025202620272028
Revenue$2.1B$1.7B$1.1B$1.5B$1.7B
EBIT Margin59%55%--55%
Net Profit$934M$690M$368M$605M$678M
Net Margin44%40%33%40%40%

Financial data powered by Morningstar, Inc.

Samsung Securities Stock Performance

Samsung Securities has current market cap of $6.5B, and enterprise value of $14B.

Market Cap Evolution


Samsung Securities' stock price is $72.47.

Samsung Securities share price increased by 3.0% in the last 30 days, and by 52.0% in the last year.

Samsung Securities has an EPS (earnings per share) of $7.73.

See more trading valuation data for Samsung Securities
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$14B$6.5B-3.0%3.0%0.3%52.0%$7.73

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Samsung Securities Valuation Multiples

Samsung Securities trades at 6.6x EV/Revenue multiple.

See NTM and 2027E valuation multiples for Samsung Securities

EV / Revenue (LTM)


Samsung Securities Financial Valuation Multiples

As of July 17, 2026, Samsung Securities has market cap of $6.5B and EV of $14B.

Samsung Securities has a P/E ratio of 6.9x.

LTMLast FY202320242025202620272028
EV/Revenue6.6x8.0x12.5x9.1x8.1x
EV/EBIT11.1x14.8x--14.8x
P/E6.9x9.4x17.6x10.7x9.5x
EV/FCF-(3.8x)(7.3x)15.9x(3.8x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Samsung Securities Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Samsung Securities Margins & Growth Rates

Samsung Securities grew revenue by 41% and net profit by 65% in the last fiscal year.

In the most recent fiscal year, Samsung Securities reported net margin of 40%.

See estimated margins and future growth rates for Samsung Securities

Samsung Securities Margins

Last FY202420252026202720282029
EBIT Margin55%-55%62%
Net Margin40%40%40%47%
FCF Margin(209%)57%(211%)-

Samsung Securities Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth41%37%12%42%
EBIT Growth61%--61%
Net Profit Growth65%64%12%68%
FCF Growth-(146%)(514%)-

Data powered by FactSet, Inc. and Morningstar, Inc.

Samsung Securities Operational KPIs

Access forward-looking KPIs for Samsung Securities
LTMLast FY202320242025202620272028
S&M Expenses to Revenue-5%6%5%5%
G&A Expenses to Revenue-7%10%8%8%
Opex to Revenue39%47%55%46%47%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Samsung Securities Competitors

Samsung Securities competitors include Zheshang Securities, Brookfield Business Corp, HuaAn Securities, Dongxing Securities, Zhongtai Securities, SDIC Capital, Motilal Oswal, Onex, Soochow Securities and TPG.

Most Samsung Securities public comparables operate across Investment Banking, Investment Brokerage and PE & VC.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Zheshang Securities11.5x10.6x--
Brookfield Business Corp1.7x-6.5x-
HuaAn Securities14.7x---
Dongxing Securities16.3x---
Zhongtai Securities9.4x9.1x--
SDIC Capital(5.3x)-(12.2x)-
Motilal Oswal7.8x7.7x16.6x16.5x
Onex6.9x-9.7x-

This data is available for Pro users. Sign up to see all Samsung Securities competitors and their valuation data.

Start Free Trial

Investments by Samsung Securities

Samsung Securities has invested in 29 companies to date.

Latest investment by Samsung Securities was on July 6th 2026. Samsung Securities invested in Fore Biotherapeutics in their $67M Series D round (EV/Revenue multiple available to Pro users).

See VC round multiples

Latest Investments by Samsung Securities

Fore Biotherapeutics
LinqAlpha
Dunamu
Automata
Description
Fore Biotherapeutics is a precision oncology biotech headquartered in Cambridge, Massachusetts. The company develops small-molecule therapies targeting undruggable mutations in RAS, PI3K, and MTAP pathways using functional genomics screening. Its lead program advances toward clinical trials for pancreatic and lung cancers. Fore Bio collaborates with academic labs and raised Series A funding in 2023.
LinqAlpha is a Boston-based generative AI platform designed for hedge fund equity research. It equips analysts with specialized search models to query financial filings, earnings transcripts, and market data from sources like SEC EDGAR and Bloomberg. Used by top multi-billion-dollar funds, it automates summarization of 10-Ks, peer comparisons, and event-driven signals to shorten research cycles.
Dunamu is a Seoul-based fintech operator of Upbit, the largest cryptocurrency exchange in South Korea with over 10 million users. It also runs Stockplus for securities trading partnered with 11 broker-dealers, U-Stockplus for OTC private company shares, and Onboard for electronic equity management. Upbit extends to Indonesia, Thailand, and Singapore markets. Founded in 2017, Dunamu processes daily trading volumes surpassing $2 billion across platforms.
Automata is a developer of AI-powered tools including AI agents and smart integrations. These products help teams plan, communicate, and work by building, managing, and evolving software workflows under human guidance. The company delivers industry-tailored AI solutions to address business challenges.
HQ CountryUnited StatesUnited StatesSouth KoreaSouth Korea
HQ City
Philadelphia, PA
-
Seoul
Daejeon
Deal Date6 Jul 20261 Jul 202627 May 202623 Apr 2026
RoundSeries DSeries ASecondarySeries A
Raised$67M$22M$417M$7M
InvestorsNovartis Venture Fund; Wellington Management; Axil Capital; LG Technology Ventures; HBM Healthcare Investments; Cormorant Asset Management; SymBiosis; 3B Future Health Fund; SR One; Primer Ventures; OrbiMed; Samsung SecuritiesHana Ventures; AVP; NH Investment & Securities; Mirae Asset Venture Investment; SV Investment; NuVentures; YJ Capital; Betatron Venture Group; Samsung Securities; GFT Ventures; Mirae Asset Capital; Atinum InvestmentSamsung Card; Samsung SDS; Samsung SecuritiesiM Investment Partners; Linear Capital; IBK Capital; We Ventures; Samsung Securities; SBI Investment KOREA
Valuationundisclosedundisclosedundisclosedundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Samsung Securities investments and their VC round multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Samsung Securities

When was Samsung Securities founded?Samsung Securities was founded in 1982.
Where is Samsung Securities headquartered?Samsung Securities is headquartered in South Korea.
Is Samsung Securities publicly listed?Yes, Samsung Securities is a public company listed on Korea Exchange.
What is the stock symbol of Samsung Securities?Samsung Securities trades under 016360 ticker.
When did Samsung Securities go public?Samsung Securities went public in 1988.
Who are competitors of Samsung Securities?Samsung Securities main competitors include Zheshang Securities, Brookfield Business Corp, HuaAn Securities, Dongxing Securities, Zhongtai Securities, SDIC Capital, Motilal Oswal, Onex, Soochow Securities, TPG.
What is the current market cap of Samsung Securities?Samsung Securities' current market cap is $6.5B.
What is the current revenue of Samsung Securities?Samsung Securities' last 12 months revenue is $2.1B.
What is the current revenue growth of Samsung Securities?Samsung Securities revenue growth (NTM/LTM) is 14%.
What is the current EV/Revenue multiple of Samsung Securities?Current revenue multiple of Samsung Securities is 6.6x.
What is the current net income of Samsung Securities?Samsung Securities' last 12 months net income is $934M.
How many companies Samsung Securities has acquired to date?Samsung Securities hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Samsung Securities has invested to date?As of July 2026, Samsung Securities has invested in 29 companies.
What was the last Samsung Securities investment?On 6th July 2026 Samsung Securities invested in Fore Biotherapeutics, participating in a $67M Series D round, alongside Novartis Venture Fund, Wellington Management, Axil Capital, LG Technology Ventures, HBM Healthcare Investments, Cormorant Asset Management, SymBiosis, 3B Future Health Fund, SR One, Primer Ventures, and 1 other investor.
In what companies Samsung Securities invested in?Samsung Securities invested in Tenstorrent, Dunamu, KREAM Corporation, Helio Health, Fore Biotherapeutics, MyRealTrip, Seoul Robotics, LinqAlpha, Point2 Technology, EVAR, Aptabio Therapeutics, AiV, Datumo, Snap Company, Select Star, Nara Space Technology, malhae, Mantra Bio, CURAUM, TeraView Holdings, and 9 other companies.

See public comps similar to Samsung Securities

Lists including Samsung Securities

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial